Avita Medical
RCEL
67 hedge funds and large institutions have $65.3M invested in Avita Medical in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 12 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
35% more capital invested
Capital invested by funds: $48.3M → $65.3M (+$17M)
0.19% less ownership
Funds ownership: 23.64% → 23.45% (-0.19%)
5% less call options, than puts
Call options by funds: $423K | Put options by funds: $447K
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 68 → 67 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$2.17M |
| 2 |
LCM
Legato Capital Management
San Francisco,
California
|
+$746K |
| 3 |
BlackRock
New York
|
+$721K |
| 4 |
Barclays
London,
United Kingdom
|
+$272K |
| 5 |
AIC
AWM Investment Company
New York
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.11M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$580K |
| 3 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$333K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$204K |
| 5 |
Bank of New York Mellon
New York
|
-$184K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWM
76
Geneos Wealth Management
Englewood,
Colorado
| – | -$82.3K | -10,392 | Closed |
|
77
Simplex Trading
Chicago,
Illinois
| – | -$33K | -3,510 | Closed |
|
|
BTI
78
Blue Trust Inc
Alpharetta,
Georgia
| – | -$321 | -20 | Closed |
|
|
CC
79
Cypress Capital
Franklin,
Tennessee
| – | -$79 | -10 | Closed |
|
RCEL Hedge Fund Activity: Q3 2024 in Review
67 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Avita Medical (RCEL) for Q3 2024, worth a combined $65.3M — up 35% from $48.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RCEL and 11 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 25 added.
The largest buyer was Essex Investment Management, opening a new position worth an estimated $2.17M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $2.11M sold.
- 67 institutional investors held Avita Medical (RCEL) as of Q3 2024, down from 68 in Q2 2024.
- Funds reported $65.3M of Avita Medical stock for Q3 2024, up 35% quarter-over-quarter.
- 11 funds opened new Avita Medical positions in Q3 2024 and 12 closed out, a net change of -1 holder.
- The largest Avita Medical buyer in Q3 2024 was Essex Investment Management, an estimated $2.17M added.
- The largest Avita Medical seller in Q3 2024 was Soleus Capital Management, an estimated $2.11M sold.
Based on aggregated 13F filings for Q3 2024.